CERRITO MARIA GRAZIA

Ilari, A., Cogliati, V., Sherif, N., Grassilli, E., Ramazzotti, D., Cordani, N., et al. (2024). Differential Expression of NOTCH-1 and Its Molecular Targets in Response to Metronomic Followed by Conventional Therapy in a Patient with Advanced Triple-Negative Breast Cancer. BIOMEDICINES, 12(2) [10.3390/biomedicines12020272]. Detail

Grassilli, E., Cerrito, M. (2023). "Ironing out" fasting-induced persister cancer cells to render chemotherapy effective: is this the solution?. EBIOMEDICINE, 90(April 2023) [10.1016/j.ebiom.2023.104542]. Detail

Cordani, N., Lisini, D., Cocce, V., Paglia, G., Meanti, R., Cerrito, M., et al. (2023). Conditioned Medium of Mesenchymal Stromal Cells Loaded with Paclitaxel Is Effective in Preclinical Models of Triple-Negative Breast Cancer (TNBC). INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 24(6), 1-16 [10.3390/ijms24065864]. Detail

Meazza Prina, M., Gotuzzo, I., Cazzaniga, M., De Bernardi, E., Cafaro, P., Capici, S., et al. (2023). Baseline 18FDG-PET Metabolic Tumour Volume (MTV) as a Potential Predictive Factor of Response to Metronomic Chemotherapy (mCHT) in HR+/HER2- Metastatic Breast Cancer (MBC) Patients (pts). Preliminary Results of the Metro-pet Study. Intervento presentato a: SABCS - San Antonio Breast Cancer Symposium - DEC 06-10, 2022, San Antonio, Texas, USA [10.1158/1538-7445.SABCS22-P6-01-42]. Detail

Cordani, N., Mologni, L., Piazza, R., Cogliati, V., Pepe, F., Capici, S., et al. (2023). Loss of CDKN2B expression as a potential marker of resistance to CDK4/6 inhibitor in Luminal Breast Cancer cells. In Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX (pp.13-21). AACR [10.1158/1538-7445.SABCS22-P1-13-21]. Detail